Drug Profile


Alternative Names: Diphenylcyclopropenone

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator Hapten Pharmaceuticals
  • Developer Hapten Pharmaceuticals; RXi Pharmaceuticals
  • Class Allergens; Antiallergics; Cyclopropanes; Haptens; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alopecia areata; Cancer metastases; Warts

Most Recent Events

  • 13 Dec 2016 Preliminary efficacy and safety data from a phase IIa trial in Warts released by RXi Pharmaceuticals
  • 30 Mar 2016 RXi Pharmaceuticals has patent protection and pending patents for diphencyprone
  • 01 Dec 2015 RXi Pharmaceuticals initiates a phase IIa trial for Warts in USA (Topical) (9189318; NCT02640820)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top